Our history
Headquartered in London, UK, NovalGen was formed in 2019. The company is based on proprietary innovations from UCL, London UK.
NovalGen’s founder is world-renowned Professor Amit Nathwani who has a track record of developing cutting edge, transformative treatments for patients. NovalGen has swiftly emerged as a leader in the immunotherapy space. Our agile approach has led to strategic collaborations with prominent institutions like St. Jude Children’s Research Hospital, MD Anderson, alongside critical partnerships with CMO manufacturers to harness expertise and scale.
Evolving into a premier immunotherapy company, NovalGen has navigated its growth trajectory with precision. Securing non-dilutive grant funding and a successful Series A funding round in 2019, backed by Convergys Capital, UCL Technology Fund, and UCL Business, underscores our commitment to innovation and excellence.
